SCHEMBL8971103

SCHEMBL8971103

OCC1=CCN(CCc2ccccc2)CC1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.51
SLC6A3 Q01959 2/20 0.50
SIGMAR1 Q99720 2/20 0.49
DRD2 P14416 2/20 0.45
DRD4 P21917 1/20 0.45
DRD3 P35462 1/20 0.45
HTR1A P08908 1/20 0.45
SLC6A4 P31645 2/20 0.44
SLC6A2 P23975 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
ACHE P22303 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
KCNH2 Q12809 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL325460 0.84 SIGMAR1 (0.50) SLC6A3SIGMAR1DRD2DRD4DRD3
SCHEMBL30484775 0.78 SIGMAR1 (0.66) MAOASLC6A3SIGMAR1DRD2DRD4
SCHEMBL8971010 0.77 MAOA (0.50) MAOASLC6A3SIGMAR1DRD2DRD4
SCHEMBL7697321 0.75 MAOA (0.51) MAOASLC6A3SIGMAR1DRD2HTR1A
SCHEMBL1588025 0.75 SIGMAR1 (0.47) SLC6A3SIGMAR1DRD2DRD4DRD3
SCHEMBL8984029 0.74 SIGMAR1 (0.50) SIGMAR1DRD2DRD4DRD3HTR1A
SCHEMBL12040689 0.74 SIGMAR1 (0.57) MAOASIGMAR1
SCHEMBL5230749 0.73 SIGMAR1 (0.44) SLC6A3SIGMAR1DRD2DRD4DRD3
SCHEMBL7868181 0.72 CCR3 (0.51) SIGMAR1DRD2DRD4DRD3HTR1A
SCHEMBL3314489 0.72 SIGMAR1 (0.46) MAOASIGMAR1KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5480892-A SIGMA RECEPTOR ANTAGONISTS; TREATMENT OF PHYSIOLOGICAL OR DRUG INDUCED PSYCHOSIS AND DYSKINESIA THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1996-01-02 US disclosed
US-5356906-A (N-phthalimidoalkyl) piperidines useful as treatments for psychosis THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1994-10-18 US disclosed
WO-1993022310-A1 (N-PHTHALIMIDOALKYL)PIPERIDINES FOR THE TREATMENT OF PSYCHOSES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1993-11-11 WO disclosed
EP-0497843-A4 (N-PHTHALIMIDOALKYL) PIPERIDINES 1992-09-23 EP disclosed
EP-0497843-A1 (N-PHTHALIMIDOALKYL) PIPERIDINES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1992-08-12 EP disclosed
WO-1991006297-A1 (N-PHTHALIMIDOALKYL) PIPERIDINES THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) 1991-05-16 WO disclosed